Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2301 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Applications only from a haematologist. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)  Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase		
Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI)  or  Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment		
and  Maximum nilotinib dose of 800 mg/day and  Subsidised for use as monotherapy only		
Note: *treatment failure as defined by Leukaemia Net Guidelines.		
Renewal  Current approval Number (if known):		
Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines  and  Nilotinib treatment remains appropriate and the patient is benefiting from treatment		
and Maximum nilotinib dose of 800 mg/day		
Subsidised for use as monotherapy only		

I confirm the above details are correct and that in signing this form I understand I may be audited.